ASSOCIATION ANALYSIS BETWEEN THE C516T POLYMORPHISM IN THE 5-HT2A RECEPTOR GENE AND SCHIZOPHRENIA

Vivian Bertola, Quirino Cordeiro, Stevin Zung, Elisabete Cristina Miracca, Homero Vallada

ABSTRACT - Data from epidemiological studies have demonstrated that genetics is an important risk factor for schizophrenia. Disturbances of serotonergic brain pathways have been implicated in the pathophysiology of schizophrenia. Some studies have suggested that the efficacy of atypical antipsychotics on schizophrenia treatment may be related to the serotonin 2A receptor (5-HT2A), and that serotonergic drugs may induce psychotic symptoms. Thus, the aim of this study was to investigate the association between the C516T polymorphism and schizophrenia in a Brazilian population composed by 246 patients and 315 healthy matched controls in a case-control approach. No statistically differences were observed in allelic ($\chi^2=1.77$, 1 d.f., $p=0.18$) or genotypic ($\chi^2=1.69$, 2 d.f., $p=0.42$) distributions between cases and controls. The results suggest that the C516T polymorphism of the 5-HT2A receptor gene is not related to the susceptibility for schizophrenia in our Brazilian sample.

KEY WORDS: serotonin, genetic association, allele, genotype, 5HT2A, schizophrenia.

Schizophrenia (SCZ) is a severe mental disorder characterized by psychotic symptoms (delusions, hallucinations), disturbances of thought, affect, volition and behavior, with late-adolescent or early adult onset and, in most cases, presenting a chronic course. The average lifetime prevalence is about 1% in general population. Evidence from family, twin and adoption studies has suggested that there is an important participation of a genetic component on the etiology of SCZ. However, the mode of inheritance is complex and non-Mendelian, but rather of a polygenic and multifactorial nature. The contribution of single relevant gene must be small, thus association studies involving case-control approaches have been employed to evaluate the allelic variations at specific candidate genes which may be related to the etiopathology of the disorder. Researches with hallucinogens drugs have suggested that serotonin (5-hydroxytryptophan: 5-HT) would be an important neurotransmitter in the pathogenesis of SCZ. The two major classes of psychotomimetics, the indoleamines and phenethylamines may hold their principal effects through a common action upon serotonin receptors. Evidences that serotonergic-depleting drugs could alleviate some symptoms of SCZ also helped to build the theory that an increase in serotonin activation may be related to the disorder. More evidences of the interest of serotonin in SCZ come from the findings by Arora and Meltzer that reported a significant decrease in the number of cerebral...
5-HT receptors in patients with SCZ as compared to the controls, negating the role of neuroleptics for this difference, and also from the results by Joyce et al. that showed that serotonin uptake sites and receptors are altered in the limbic system of patients with the disorder.

Fourteen known 5-HT receptors subtypes are involved in serotonin action. Among the 5-HT receptors, the 5-HT subtype 2A receptor (5-HT2A) is highly expressed in the neocortex, limbic region, and the basal ganglia, and has been focused as one of the major target for atypical antipsychotics, like olanzapine and clozapine, through receptor affinity and binding studies. The 5-HT2A is a G-protein-coupled receptor (GPCR) seven transmembrane domains whose activation leads to the stimulation of the enzyme phospholipase C and to the subsequent hydrolysis of the membrane phosphoinositides, with the synthesis of the second messengers, inositol triphosphate and diacylglycerol. The 5-HT2A gene was mapped by Sparkes et al. on chromosome 13q14.2, which has been known as a promising chromosomal region could harbor candidate genes for SCZ through some linkage studies. A meta-analysis of whole-genome linkage scans confirmed linkage between SCZ and markers on the long arm of chromosome 13. The 5-HT2A gene consists of 3 exons separated by 2 introns and spans over 20 kb. At least seven single nucleotide polymorphisms (SNPs) are located within the coding region of the human 5-HT2A receptor gene. Five of the seven nucleotide polymorphisms (T25N, I197V, S421F, A447V, and H452Y) result in amino-acid mutations (non-synonymous SNPs). The remaining two of the seven nucleotide polymorphisms (T102C and C516T) do not alter the 5-HT2A receptor amino-acid sequence (synonymous SNPs).

In the present study, the silent C516T polymorphism was investigated as a possible risk factor for SCZ.

**METHOD**

**Sample** – All controls, parents and schizophrenic patients provided written informed consent. The ethical approval for the study was obtained from the Ethics Committee at the Hospital das Clínicas, University of São Paulo Medical School (CAPPesq). A) Patients sample: 246 patients were recruited from inpatient and outpatient services at the Institute of Psychiatry of the Hospital das Clínicas, University of São Paulo Medical School and diagnosed according to DSM-IV criteria for SCZ. B) Controls sample: 315 age and sex matched healthy controls were recruited from the Blood Donation Service at the Hospital das Clínicas, University of São Paulo Medical School.

**Genotyping** – We collected ten milli-liters of venous blood from each subject and genomic DNA was extracted from lymphocytes using “salting out” protocol. The sequence containing the C516T variant in the 5HT2A gene was amplified by PCR using primers described in Arranz et al. The amplified products were digested with Sau96I restriction enzyme and the genotype was determined after electrophoresis on ethidium bromide stained 2% of the agarose gels. The C516 allele showed fragments of 109 and 87 base pairs, whereas the T516 allele remained uncut.

To avoid errors, genotyping was read by two independently trained research technicians. When a disagreement arose the genotyping was repeated. In addition, random re-genotyping was repeated in 20% of the sample.

**Statistical analysis** – The statistical power of the sample was evaluated using the CaTS Program (Center for Statistical Genetics – The University of Michigan) (http://www.sph.umich.edu/csg/abecasis/CaTS/index.html). The Hardy-Weinberg equilibrium test was performed by HWE program. Chi-square test, used to investigate possible association between genotypes, alleles and homogyzosity with SCZ, was performed by the EpInfo version 6.0. The significance level for all the statistical tests was 0.05.

**RESULTS**

The power of the sample, based on 246 patients and 315 controls, disorder prevalence of 1%, average allelic frequency around 4%, multiplicative model with the genotype relative risk = 2.0, and significance level of 0.05, was 74%.

There were no significant deviations from the Hard-Weinberg equilibrium in any of the sample for the polymorphism studied (patients p=0.09 and controls p=0.08).

Case-control analysis provided no differences in genotypic (\(\chi^2=1.69, p=0.42, 2d.f.\)) and allelic (\(\chi^2=1.77, p=0.18, 1d.f.\)) distributions between patients and controls samples (Table). There was no association bet-

**Table. Distributions of the C516T alleles and genotypes frequencies in SCZ patients and controls samples.**

<table>
<thead>
<tr>
<th>Alleles</th>
<th>SCZ (%)</th>
<th>Controls (%)</th>
<th>(\chi^2)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>477 (96.9)</td>
<td>601 (95.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>15 (3.0)</td>
<td>29 (4.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>492 (100)</td>
<td>630 (100)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>SCZ (%)</th>
<th>Controls (%)</th>
<th>(\chi^2)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC</td>
<td>232 (94.3)</td>
<td>288 (91.4)</td>
<td>1.69</td>
<td>0.42</td>
</tr>
<tr>
<td>CT</td>
<td>13 (4.8)</td>
<td>25 (7.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>1 (0.4)</td>
<td>2 (0.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>246 (100)</td>
<td>315 (100)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ween homozigosity and SCZ as well ($\chi^2 = 1.54$, $p = 0.21$, 1 d.f.).

**DISCUSSION**

Due the evidences of involvement of the serotonergic system in the pathophysiology of SCZ, many studies have been carried out with polymorphisms of this cerebral pathway and SCZ. The 5-HT2A polymorphisms have been the most investigated because of its cerebral location, role on atypical antipsychotics action, and interesting chromosomal positional of its gene. Among the 5-HT2A polymorphisms, the T102C has been the most investigated in SCZ, however with inconclusive results according to recent meta-analysis. Other serotoninergic polymorphisms of 5-HT2A have also been studied, like the C516T, not only in SCZ susceptibility. Studies with other psychiatric disorders showed lack of association with bipolar disorder and association with obsessive-compulsive disorder.

In the present investigation we tested the association of the C516T polymorphism of 5-HT2A and SCZ. However, the results did not support the hypothesis that this polymorphism has a main role in the development of SCZ in our sample. We have found no evidence for allelic or genotypic association between the disorder and such polymorphism. These findings are in concordance with previous investigation that also showed negative result.

We also tested if there was association between homozygosity and SCZ. There are some reports showing association of homozygosity of other genetic polymorphisms, like the Ser9Gly of the dopamine receptor subtype 3 (DRD3), and SCZ. This type of association may represent a heterozygosity advantage, probably because the presence of two different molecular forms of the neurotransmitter receptor, resulting in an increased ability to respond adaptively to variations in the environment happening either in neural development or adult life. However, in our sample there was not found such association as well. This lack of association may occur due to the low frequency of the C516T polymorphism in the population what requires big samples for the analyses. Other possible limitation of the present investigation is related to the population stratification. Investigations comparing different ethnic populations have shown significant variations in the allelic frequency. Power to detect association may be reduced in ethnic admixture samples. In order to face such a problem we can try to identify the ethnic origin of the sample and try to compound homogeneous samples. However in Brazil physical characteristics such as skin pigmentation, hair color and texture, shape of the nose and lips, are poor predictors of genomic ancestry what difficult the ethnic matching in our case-controls studies. Nevertheless the fact that the present sample is in Hardy-Weinberg equilibrium indicates that our sample may not have important problems of population stratification. Moreover, ethnic matching conducted using genetic markers was performed in part of our sample in a case-control study with cocaine dependence and the results showed that despite the ethnic admixture in Brazil the ethnic stratification was not a bias in that case.

Otherwise, the 5-HT2A gene is expressed in various tissues and brain regions, and therefore is likely to be under a complex expression control. There could be different regulatory elements for different cell types, different developmental stages, and even different environments what indicate that its possible role in the pathogenesis of SCZ is not easy to be approached.

In conclusion, the results of this work do not provide evidence of association between SCZ and alleles or genotypes of the C516T polymorphism in the 5-HT2A gene with the disorder in the studied sample.

**REFERENCES**


